194 related articles for article (PubMed ID: 28510609)
1. SPR-based fragment screening with neurotensin receptor 1 generates novel small molecule ligands.
Huber S; Casagrande F; Hug MN; Wang L; Heine P; Kummer L; Plückthun A; Hennig M
PLoS One; 2017; 12(5):e0175842. PubMed ID: 28510609
[TBL] [Abstract][Full Text] [Related]
2. In Silico Investigation of the Neurotensin Receptor 1 Binding Site: Overlapping Binding Modes for Small Molecule Antagonists and the Endogenous Peptide Agonist.
Lückmann M; Holst B; Schwartz TW; Frimurer TM
Mol Inform; 2016 Jan; 35(1):19-24. PubMed ID: 27491650
[TBL] [Abstract][Full Text] [Related]
3. Optimization and
Bumbak F; Keen AC; Gunn NJ; Gooley PR; Bathgate RAD; Scott DJ
Biochim Biophys Acta Biomembr; 2018 Jun; 1860(6):1372-1383. PubMed ID: 29596791
[TBL] [Abstract][Full Text] [Related]
4. Discovery of novel antagonists of human neurotensin receptor 1 on the basis of ligand and protein structure.
Zhang G; Wang K; Li XD; Zhang DL; Xu F
Biomed Pharmacother; 2016 Dec; 84():147-157. PubMed ID: 27643557
[TBL] [Abstract][Full Text] [Related]
5. Direct analysis of a GPCR-agonist interaction by surface plasmon resonance.
Harding PJ; Hadingham TC; McDonnell JM; Watts A
Eur Biophys J; 2006 Oct; 35(8):709-12. PubMed ID: 16708210
[TBL] [Abstract][Full Text] [Related]
6. Ligand Discovery for a Peptide-Binding GPCR by Structure-Based Screening of Fragment- and Lead-Like Chemical Libraries.
Ranganathan A; Heine P; Rudling A; Plückthun A; Kummer L; Carlsson J
ACS Chem Biol; 2017 Mar; 12(3):735-745. PubMed ID: 28032980
[TBL] [Abstract][Full Text] [Related]
7. Intermolecular interactions between the neurotensin and the third extracellular loop of human neurotensin 1 receptor.
Da Costa G; Bondon A; Coutant J; Curmi P; Monti JP
J Biomol Struct Dyn; 2013 Dec; 31(12):1381-92. PubMed ID: 23140271
[TBL] [Abstract][Full Text] [Related]
8. A Fragment-Based Ligand Screen Against Part of a Large Protein Machine: The ND1 Domains of the AAA+ ATPase p97/VCP.
Chimenti MS; Bulfer SL; Neitz RJ; Renslo AR; Jacobson MP; James TL; Arkin MR; Kelly MJ
J Biomol Screen; 2015 Jul; 20(6):788-800. PubMed ID: 25690569
[TBL] [Abstract][Full Text] [Related]
9. Virtual screening of a natural compound library at orthosteric and allosteric binding sites of the neurotensin receptor.
Rejwan Ali M; Sadoqi M; Boutajangout A; Mezei M
J Biomol Struct Dyn; 2019 Oct; 37(17):4494-4506. PubMed ID: 30479178
[TBL] [Abstract][Full Text] [Related]
10. A comparative study of fragment screening methods on the p38α kinase: new methods, new insights.
Pollack SJ; Beyer KS; Lock C; Müller I; Sheppard D; Lipkin M; Hardick D; Blurton P; Leonard PM; Hubbard PA; Todd D; Richardson CM; Ahrens T; Baader M; Hafenbradl DO; Hilyard K; Bürli RW
J Comput Aided Mol Des; 2011 Jul; 25(7):677-87. PubMed ID: 21732248
[TBL] [Abstract][Full Text] [Related]
11. The amide linker in nonpeptide neurotensin receptor ligands plays a key role in calcium signaling at the neurotensin receptor type 2.
Thomas JB; Giddings AM; Olepu S; Wiethe RW; Warner KR; Sarret P; Longpre JM; Runyon SP; Gilmour BP
Bioorg Med Chem Lett; 2015; 25(10):2060-4. PubMed ID: 25881832
[TBL] [Abstract][Full Text] [Related]
12. Establish an automated flow injection ESI-MS method for the screening of fragment based libraries: Application to Hsp90.
Riccardi Sirtori F; Caronni D; Colombo M; Dalvit C; Paolucci M; Regazzoni L; Visco C; Fogliatto G
Eur J Pharm Sci; 2015 Aug; 76():83-94. PubMed ID: 25952103
[TBL] [Abstract][Full Text] [Related]
13. Complementarity between in silico and biophysical screening approaches in fragment-based lead discovery against the A(2A) adenosine receptor.
Chen D; Ranganathan A; IJzerman AP; Siegal G; Carlsson J
J Chem Inf Model; 2013 Oct; 53(10):2701-14. PubMed ID: 23971943
[TBL] [Abstract][Full Text] [Related]
14. [Progress in the fragment-based drug discovery].
Ren J; Li J; Shi F; Wang X; He JH; Xu YC; Zhang NX; Xiong B; Shen JK
Yao Xue Xue Bao; 2013 Jan; 48(1):14-24. PubMed ID: 23600136
[TBL] [Abstract][Full Text] [Related]
15. Activation Dynamics of the Neurotensin G Protein-Coupled Receptor 1.
Cong X; Fiorucci S; Golebiowski J
J Chem Theory Comput; 2018 Aug; 14(8):4467-4473. PubMed ID: 29965755
[TBL] [Abstract][Full Text] [Related]
16. Process of Fragment-Based Lead Discovery-A Perspective from NMR.
Ma R; Wang P; Wu J; Ruan K
Molecules; 2016 Jul; 21(7):. PubMed ID: 27438813
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic approaches targeting the neurotensin receptors.
Iyer MR; Kunos G
Expert Opin Ther Pat; 2021 May; 31(5):361-386. PubMed ID: 33393392
[No Abstract] [Full Text] [Related]
18. Structure-Based Virtual Screening.
Li Q; Shah S
Methods Mol Biol; 2017; 1558():111-124. PubMed ID: 28150235
[TBL] [Abstract][Full Text] [Related]
19. Target immobilization as a strategy for NMR-based fragment screening: comparison of TINS, STD, and SPR for fragment hit identification.
Kobayashi M; Retra K; Figaroa F; Hollander JG; Ab E; Heetebrij RJ; Irth H; Siegal G
J Biomol Screen; 2010 Sep; 15(8):978-89. PubMed ID: 20817886
[TBL] [Abstract][Full Text] [Related]
20. NMR-Fragment Based Virtual Screening: A Brief Overview.
Singh M; Tam B; Akabayov B
Molecules; 2018 Jan; 23(2):. PubMed ID: 29370102
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
